Table 1. Baseline Characteristics of the Atherosclerotic Cardiovascular Disease Patient Population in the FOURIER Trial and US Population From NHANES.
| Characteristic | FOURIER Trial | NHANES | |
|---|---|---|---|
| LDL-C ≥70 mg/dL | LDL-C ≥100 mg/dL | ||
| Age, mean (SD), y | 63 (9) | 66 (11) | 64 (12) |
| Male sex, No. (%) | 20 795 (75) | 4 942 898 (61) | 1 983 383 (59) |
| Race/ethnicity, No. (%) | |||
| White | 23 426 (85) | 6 395 502 (78) | 2 483 397 (74) |
| Black or African American | 699 (2) | 659 089 (8) | 378 565 (11) |
| Asian or other | 3439 (12) | 1 109 929 (14) | 483 231 (14) |
| Cardiovascular risk factors, No. (%) | |||
| Hypertension | 22 040 (80) | 6 082 104 (74) | 2 576 980 (77) |
| Diabetes mellitus | 9333 (34) | 2 102 232 (26) | 913 607 (27) |
| Current cigarette use | 7770 (28) | 2 083 283 (26) | 682 855 (20) |
| History of vascular disease, No. (%)a | |||
| Myocardial infarction | 22 356 (71) | 4 233 427 (52) | 1 481 045 (44) |
| Ischemic stroke | 5330 (17) | 2 793 056 (34) | 909 851 (27) |
| Other ASCVD | 3640 (12) | 1 138 038 (14) | 954 297 (29) |
| Ezetimibe use, No. (%) | 1393 (5) | 571 044 (7) | 178 285 (5) |
| Lipid parameters at parent study baseline | |||
| LDL-C, mean (SD), mg/dL | 97 (28) | 104 (28) | 130 (27) |
| LDL-C 70-99 mg/dL, No. (%) | 15 586 (57) | 4 819 328 (59) | 0 |
| LDL-C ≥100 mg/dL, No. (%) | 9943 (36) | 3 345 193 (41) | 3 345 193 (100) |
| HDL-C, mean (SD), mg/dL | 46 (13) | 50 (12) | 48 (11) |
| Triglycerides, mean (SD), mg/dL | 149 (70) | 138 (74) | 164 (85) |
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NHANES, National Health and Nutrition Examination Surveys.
SI conversion factor: To convert cholesterol levels to millimoles per liter, multiply by 0.0259; to convert triglycerides to millimoles per liter, multiply by 0.0113.
a
Percentage split in the history of vascular disease is calculated using the total number of previous events, rather than the total number of study participants, as is used for the other characteristics.